Ekso Bionics (NASDAQ:EKSO) Raised to “Hold” at Wall Street Zen

Ekso Bionics (NASDAQ:EKSO) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Several other equities analysts have also weighed in on EKSO. HC Wainwright set a $6.00 price objective on Ekso Bionics and gave the company a “buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ekso Bionics in a research report on Monday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Ekso Bionics presently has a consensus rating of “Hold” and a consensus target price of $115.50.

Ekso Bionics Price Performance

EKSO opened at $4.67 on Friday. Ekso Bionics has a 1 year low of $2.73 and a 1 year high of $14.97. The company’s 50 day simple moving average is $4.78 and its 200 day simple moving average is $4.18. The stock has a market capitalization of $12.24 million, a PE ratio of -0.82 and a beta of 0.82. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.45. The business had revenue of $4.23 million during the quarter, compared to the consensus estimate of $4.16 million. Ekso Bionics had a negative return on equity of 90.71% and a negative net margin of 70.74%. As a group, sell-side analysts expect that Ekso Bionics will post -0.48 EPS for the current year.

Insiders Place Their Bets

In other Ekso Bionics news, CEO Scott G. Davis sold 23,315 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $4.80, for a total value of $111,912.00. Following the completion of the transaction, the chief executive officer directly owned 78,777 shares of the company’s stock, valued at $378,129.60. This represents a 22.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Jerome Wong sold 11,288 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $4.80, for a total value of $54,182.40. Following the completion of the transaction, the chief financial officer owned 26,009 shares in the company, valued at approximately $124,843.20. This trade represents a 30.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 6.00% of the company’s stock.

Institutional Trading of Ekso Bionics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC boosted its stake in Ekso Bionics by 18.4% during the 1st quarter. Armistice Capital LLC now owns 2,042,382 shares of the company’s stock valued at $823,000 after acquiring an additional 316,733 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Ekso Bionics in the 3rd quarter worth about $198,000. Shay Capital LLC acquired a new stake in shares of Ekso Bionics in the 3rd quarter valued at about $67,000. Virtu Financial LLC bought a new position in shares of Ekso Bionics during the third quarter worth about $57,000. Finally, Consolidated Portfolio Review Corp acquired a new position in Ekso Bionics in the third quarter worth about $333,000. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.